期刊文献+

恶性肿瘤骨转移疼痛患者治疗及预后的临床分析 被引量:18

Clinical Analysis of Treatment and Prognosis of Patients with Pain Caused by Malignant Bone Metastasis
下载PDF
导出
摘要 目的分析骨转移患者骨痛发病特点、内科治疗效果及预后,并对镇痛药物用药合理性进行分析,以提高临床对骨转移疼痛的诊治水平。方法对123例伴有疼痛的恶性肿瘤骨转移患者进行规范三阶梯止痛治疗及抗肿瘤治疗,并对其临床特征进行回顾性分析。结果总疼痛缓解率85.4%,疼痛程度明显减轻(P<0.05)。各麻醉类药物DUI值均接近1,用药趋向合理。Kaplan-Meier生存分析显示,中度疼痛者生存明显优于重度疼痛者(P=0.015);疼痛明显缓解者生存明显优于未明显缓解者(P=0.021);无内脏转移者生存优于伴有内脏转移者(P=0.000)。COX多因素分析结果显示,疼痛程度、是否内脏转移是影响预后的独立危险因素。结论规范治疗可使多数骨转移疼痛患者症状改善,并在一定程度上延长生存时间。阿片类药物对中重度疼痛具有理想的止痛效果,不良反应可以耐受。 Objective To analyze the clinical features,therapeutic effect and prognosis in patients with bone pain induced by malignant bone me-tastasis as well as the rationality of analgesic application,so as to improve the level of diagnosis and treatment for metastatic bone pain. Methods Totally 123 patients with pain due to malignant bone metastasis received antitumor therapy and analgesic therapy based on standardized three-step guidelines. Their clinical characteristics were retrospectively analyzed. Results The total pain relief rate was 85.4%and the pain was significantly relieved(P〈0.05). The DUI value of each narcotic agent was close to 1 and the application of narcotic agents tended to be rational. The Kaplan-Meier survival analysis showed that patients with moderate pain had longer survival time than those with severe pain(P=0.015). The survival rate of patients with significant pain relief after treatment was higher than those unrelieved(P=0.021). The survival rate of patients without visceral me-tastasis was higher than those with visceral metastasis(P=0.000). The COX multivariate analysis indicated that the pain intensity and visceral me-tastasis were independent risk factors influencing patient prognosis. Conclusion Standard treatment can improve symptoms in most patients with bone metastasis and prolong survival time. Opioids have satisfactory analgesic effect for moderate to severe pain and the adverse reactions can be tol-erated.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2015年第5期443-447,共5页 Journal of China Medical University
关键词 骨转移 疼痛 临床分析 生存期 用药合理性 bone metastasis pain clinical analysis survival time medication rationality
  • 相关文献

参考文献8

  • 1Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity [J]. Clin Cancer Res, 2010, 12 (20 Pt 2) : 6243s-6249s.
  • 2李琼,吴明富,宋安萍,魏军成,徐刚,卢运萍,马丁.浸润性乳腺导管癌组织中Ezrin和钙粘素E的表达与淋巴结转移的关系[J].癌症,2006,25(3):363-366. 被引量:53
  • 3刘鲁川.麻醉药品临床使用与规范化管理培训教材[M].北京:红旗出版社,2005:99.
  • 4Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain [J]. Cancer Res, 2010, 61 (10) : 4038-4047.
  • 5Faeehini G, Caraglia M, Santini D, et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronie aeid is inversely correlated to skeletal related events (SRE) [J]. J Exp Clin Cancer Res,2010,26(3): 307-312.
  • 6Coleman RE. Metastatic bone disease: clinical features, pathophysi- ology and treatment strategies [J]. Cancer Treat Rev, 2012,27 (2) : 165-176.
  • 7于世英,孙燕,张海春,吴一龙,秦叔逵,谢广茹,刘淑俊,隋广杰.芬太尼透皮贴剂治疗老年癌痛病人(英文)[J].The Chinese-German Journal of Clinical Oncology,2004,3(2):85-89. 被引量:2
  • 8Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site [J]. Psyehooneology, 2001,10 (1) : 19-28.

二级参考文献14

  • 1Martin T A, Harrison G, Mansel RE, et al. The role of the CD44/ezrin complex in cancer metastasis [J]. Crit Rev Oncol Hematol, 2003,46(2) : 165-186.
  • 2McClatchey A I. Merlin and ERM proteins: unappreciated roles in cancer development? [J]. Cancer, 2003,3 (11):877-884.
  • 3Bretscher A, Edwards K, Fehon R G, et al. ERM proteins and merlin: integrators at the cell cortex [J ]. Nature Rev Mol Cell Biol, 2002,3(8) :586-599.
  • 4Charpin C, Garcia S, Bouvier C, et al. E-CD quantitative immunohistochemistry assays in breast carcinomas [J]. J Pathol, 1997, 181 (3) : 294-300.
  • 5Hiscox S, Jiang W G. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with Ecadherin/b-catenin[J]. J Cell Sci, 1999,112(18):3081-3090.
  • 6Pujuguent P, Del Maestro L, Gautreau A, et al. Ezrin regulates E-Cadherin-dependent adherens junction assembly through Racl activation [J]. Mol Biol Cell, 2003,14 (5):2181-2191.
  • 7Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators[J]. Nat Med, 2004,10(2): 175-256.
  • 8Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis [J]. Nat Med, 2004,10(2) : 182-188.
  • 9Nestl A, Von Stein O D, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors [J]. Cancer Res, 2001,61 (4):1569-1577.
  • 10Hunt K W. Ezrin, a key component in tumor metastasis [J].Trends Mol Med, 2004,10(5) :201-205.

共引文献53

同被引文献131

引证文献18

二级引证文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部